KOSDAQBiotech & Pharma378800

Shaperon

₩2,115▲ 11.02%2026-11-18 close
Market Cap
₩19.6B
Turnover
₩200M
Volume
110K
Shares out.
9.3M
PER
—
PBR
1.2×
EPS
-₩1,297
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Shaperon: Beauty Consolidation and the Licensing Test

Shaperon's revenue rose to KRW 4.63 billion in Q3 2026 after it began consolidating a beauty subsidiary, but its operating losses have not yet turned around.

  1. 1

    Q3 2026 revenue of KRW 4.63 billion rose 11,148.5% from the prior quarter, reflecting the first consolidation of the beauty subsidiary acquired in July.

  2. 2

    The operating loss was KRW 15.8 billion in 2025, a loss in each of the four years from 2022 through 2025, and losses have continued in each of the five quarters through Q3 2026.

  3. 3

    The core of the business is licensing out its drug pipeline, and the company said it is reviewing a package technology export with overseas pharmaceutical firms.

  4. 4

    The company has set December 3, 2026 as its target for removal from the administrative issue list, which requires closing prices of at least KRW 1,000 for 45 consecutive trading days after relisting.

  5. 5

    The debt ratio fell to 12.7% at the end of 2025, the lowest of 2022 through 2025, but operating cash flow was -KRW 14.5 billion in 2025.

02

Business structure

Shaperon is a drug-discovery company focused on R&D, founded in October 2008. The company has built its pipeline around an inflammasome-regulation technology and a nanobody-drug conjugate (NDC) platform, and it targets licensing of its first-generation pipeline and early out-licensing of second-generation candidates.

The pipeline status includes completed dosing in Part 2 of a US Phase 2b trial for an atopic dermatitis drug, a completed domestic Phase 1 trial for an Alzheimer's dementia drug, and the AIDEN AI drug-discovery platform.

Revenue from drug development is lumpy, because it depends on whether licensing deals are signed as clinical programs advance.

The company built a virtual data room from more than 100 patents and regulatory submissions and is reviewing a package technology export with overseas pharmaceutical firms under non-disclosure agreements.

In July 2026 Shaperon acquired a 60% stake in NeedsTech, a beauty and home-healthcare company, and secured a right of first refusal on the remaining shares. Shaperon supplies proprietary ingredients, while the subsidiary handles product planning and branding and marketing.

The company said the subsidiary has about 110,000 members on its own shopping site and about 80,000 friends on its KakaoTalk channel, and one report put the subsidiary's 2025 revenue at KRW 17 billion. The first beauty product, launched in October 2026, is marketed under the name Truseon Spotdam.

The subsidiary was not included in consolidated 2025 revenue and has been consolidated since Q3 2026. Consolidated sales are therefore shifting from licensing-driven income toward consumer-product sales, and the beauty share will be read from the quarterly revenue trend.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩200M-₩4.4B−2617.5%
2025Q4₩48,420,246-₩4.4B−9183.7%
2026Q1₩65,400,036-₩3.7B−5607.8%
2026Q2₩41,172,633-₩3.1B−7565.0%
2026Q3₩4.6B-₩3.9B−84.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2B-₩11B-₩10.7B−551.5%−36.5%20.1%
2023₩200M-₩13.2B-₩12.4B−6145.5%−65.3%31.7%
2024₩17,704,497-₩15.1B-₩14.9B−85523.5%−93.1%20.5%
2025₩200M-₩15.8B-₩15.5B−6952.9%−62.8%12.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported annual basis, revenue went from KRW 2 billion in 2022 to KRW 215 million in 2023 (down 89.2% year on year), then to KRW 17.7 million in 2024 (down 91.8%), before recovering to KRW 228 million in 2025 (up 1,186.7%). Among 2022 to 2025, 2022 was the largest year and 2024 the smallest.

The operating loss widened every year, from KRW 11 billion in 2022 to KRW 13.2 billion, KRW 15.1 billion and KRW 15.8 billion in 2025, and the company has reported losses for four consecutive years from 2022 through 2025.

The net loss attributable to controlling shareholders grew from KRW 10.7 billion in 2022 to KRW 15.5 billion in 2025, and the total net loss including non-controlling interests was reported at the same amounts.

The operating margin was -551.5% in 2022, -6,145.5% in 2023, -85,523.5% in 2024 and -6,952.9% in 2025, reflecting losses that were very large relative to revenue. Reports attributed the operating loss mainly to the burden of drug-development costs.

Operating cash flow was negative every year, at -KRW 7.95 billion in 2022, -KRW 13 billion in 2023, -KRW 16.7 billion in 2024 and -KRW 14.5 billion in 2025.

The debt ratio fell from 20.1% in 2022 to 31.7% in 2023, 20.5% in 2024 and 12.7% in 2025, and at the end of 2025 total equity of KRW 24.7 billion was entirely attributable to controlling shareholders, against total liabilities of KRW 3.13 billion.

On a quarterly basis, revenue was KRW 168 million in Q3 2025, KRW 48.42 million in Q4 2025, KRW 65.4 million in Q1 2026 and KRW 41.17 million in Q2 2026, then jumped to KRW 4.63 billion in Q3 2026, up 11,148.5% from the prior quarter and 2,663.6% from a year earlier.

The operating loss in Q3 2026 was KRW 3.91 billion, narrower than KRW 4.39 billion in Q3 2025 but wider than KRW 3.11 billion in Q2 2026. Revenue rose to KRW 4.63 billion while an operating loss remained, which means the profit from the consolidated beauty business did not offset research and administrative costs.

Over the last four quarters, from Q4 2025 through Q3 2026, the net loss attributable to controlling shareholders totaled KRW 15.6 billion.

05

Industry analysis

Drug-development companies recognize revenue unevenly, depending on how clinical programs advance and when licensing deals are signed. Within the same biopharma sector, companies that earn product sales and companies that depend on licensing milestones show very different earnings patterns.

Licensing-focused listed peers such as Alteogen, LigaChem Biosciences and ABL Bio are often compared with Shaperon, but Shaperon's revenue base is still small by comparison. The company points to its inflammasome-regulation technology and its nanobody-drug conjugate platform as its differentiators.

The value of those technologies, however, has to be judged through the clinical data of individual programs such as the Phase 2b atopic dermatitis study and the Phase 1 Alzheimer's study.

Large listed companies such as Samsung Biologics and Celltrion lead the sector through manufacturing and product sales scale, while Shaperon's structure leans toward development and licensing.

The beauty business depends on cosmetics distribution and overseas channel expansion, where speed of product launches and marketing efficiency shape competitiveness. The subsidiary is pushing to expand overseas distribution using its own shopping-site members and KakaoTalk channel customers.

The size and timing of global licensing deals depend on pharmaceutical companies' pipeline demand, so Shaperon's position within the sector is best tracked through the accumulation of disclosed deals.

06

Outlook

The company has set three business goals. First, overseas sales of KRW 5 billion in the second half of 2026 and more than KRW 10 billion in 2027. Second, an expansion of its functional cosmetics lineup in the first half of 2027.

Third, a package technology export of its first-generation pipeline and early out-licensing of second-generation candidates. The overseas sales target and the lineup expansion have stated timelines, while the company has not specified when the licensing deals will be signed.

On the clinical side, the atopic dermatitis drug has completed dosing in Part 2 of a US Phase 2b trial, so the timing of the results is the next checkpoint. The Alzheimer's dementia drug has finished a domestic Phase 1 trial, and its next-stage plans should be confirmed through company disclosures.

On listing status, the removal requirement is closing prices of at least KRW 1,000 for 45 consecutive trading days after relisting, and the company has set December 3, 2026 as its target date.

On financials, the subsidiary has been consolidated since Q3 2026, so the 2026 annual report will include only about three months of its beauty sales.

The 2026 annual report must be filed by the end of March 2027, when the relationship between beauty revenue and the operating loss can be checked against reported figures.

07

Valuation

PER
—
PBR
1.2×
ROE
-161.4%
EPS
-₩1,297
BPS
₩1,585
Dividend per share
₩0

Because the company has reported net losses over the last four quarters, its PER cannot be calculated. The price-to-book multiple was very high at the end of Q3 2025, when the equity base was small, and it moved closer to book value after total equity rose to about KRW 24.7 billion at the end of 2025.

The company pays no dividend, so its dividend yield sits well below the sector average. Because operating losses have run since 2022, the price-to-book multiple has moved sharply with changes in the equity base.

Because multiples alone cannot explain a change in the loss structure, the valuation discussion centers on the size and timing of licensing deals and on whether beauty revenue persists quarter after quarter.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

A Growing Beauty Revenue Base

Q3 2026 revenue of KRW 4.63 billion compares with KRW 168 million in Q3 2025. The subsidiary has a base of members on its own shopping site and KakaoTalk channel customers, and the company set a target of KRW 5 billion in overseas sales for the second half of 2026. The company describes this revenue as a steady source of funds for drug development.

Licensing Talks in Progress

The company said it built a virtual data room from more than 100 patents and regulatory submissions and is reviewing a package technology export with overseas pharmaceutical firms.

If first-generation licensing or early out-licensing of second-generation candidates is completed, it could change the operating loss structure. The timing and terms have not been disclosed.

Clinical Pipeline Progress

The atopic dermatitis drug has completed dosing in Part 2 of a US Phase 2b trial, and the Alzheimer's dementia drug has finished a domestic Phase 1 trial. The company said it is widening its pipeline with the AIDEN AI drug-discovery platform.

Clinical data can support licensing negotiations, so progress at this stage serves as a reference point for the business's value.

09

Bear factors

Persistent Operating Losses

The operating loss was KRW 15.8 billion in 2025 and the net loss attributable to controlling shareholders was KRW 15.5 billion, extending four years of losses. The Q3 2026 operating loss of KRW 3.91 billion narrowed from a year earlier but widened from KRW 3.11 billion in Q2 2026. Operating cash flow was negative in every year from 2022 through 2025.

The Nature of the Revenue Jump

The Q3 2026 revenue jump came from consolidating the subsidiary, so it is hard to read as an improvement in the drug-development business. Revenue before consolidation remained small, at KRW 65.4 million in Q1 2026 and KRW 41.17 million in Q2 2026. Whether quarterly revenue continues after consolidation is the point to watch.

Listing Maintenance and Funding

The administrative designation was triggered by failing a share-price requirement, and the company completed a five-to-one reverse split, with trading halted for about 25 days before relisting on September 29. The company targets removal on December 3, 2026, but the timetable could slip if the requirement is not met.

With operating losses continuing, the company may need additional funding, and that possibility cannot be ruled out.

10

Risk factors

Clinical and licensing risk

Each clinical stage of a drug candidate carries a risk of failure, and without licensing deals revenue and cash inflows will not rise. The timing and terms of the first-generation technology export and early second-generation licensing have not been disclosed.

Until the atopic dermatitis Phase 2b results and the Alzheimer's next-stage plan are released, outside observers will find it hard to gauge pipeline value.

Beauty business growth risk

The company set targets of KRW 5 billion in overseas sales for the second half of 2026 and more than KRW 10 billion in 2027, but cosmetics distribution and overseas expansion depend on local regulation and marketing spend.

Shaperon holds a 60% stake in the subsidiary, and the remaining shares are subject to its right of first refusal. If quarterly revenue does not persist after consolidation, the volatility of consolidated sales could increase.

Financial and listing risk

Operating cash flow was -KRW 14.5 billion in 2025, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 15.6 billion.

Removal from the administrative list requires closing prices of at least KRW 1,000 for 45 consecutive trading days after relisting, and that must be met by the company's December 3, 2026 target. If capital must be raised, share issuance could dilute existing holders.

11

What to watch next

  1. December 3, 2026 (company target)

    This is the company's target date for removal from the administrative list. The checkpoint is whether the 45-consecutive-trading-day closing requirement at KRW 1,000 or above has been met.

  2. End of the second half of 2026

    Whether the company reaches its KRW 5 billion overseas sales target for the second half of 2026. Progress will be checked against the subsidiary's quarterly overseas sales disclosures.

  3. End of March 2027, the filing deadline for the 2026 annual report

    This is when the 2026 annual results are formally reported. Because the subsidiary was consolidated for only about three months, beauty revenue and the operating loss trend will be checked on an annual basis.

  4. First half of 2027

    Whether the planned expansion of the functional cosmetics lineup is carried out. Product launches would show how the beauty revenue mix changes.

  5. Timing not yet announced

    The results of the US Phase 2b trial for the atopic dermatitis drug and whether a first-generation pipeline technology export contract is signed. Both need to be confirmed through company disclosures for timing.

12

Overall view

Shaperon's Q3 2026 revenue of KRW 4.63 billion reflects the consolidation of a beauty subsidiary, while its drug-development revenue still depends on licensing deals. On reported figures, the operating loss has run for four consecutive years from 2022 through 2025 and for five consecutive quarters through Q3 2026.

The net loss attributable to controlling shareholders over the last four quarters totaled KRW 15.6 billion, and operating cash flow was -KRW 14.5 billion in 2025. On the other hand, total equity of KRW 24.7 billion and a debt ratio of 12.7% at the end of 2025 represent the lowest debt burden of 2022 through 2025.

The bullish factors are the beauty revenue base, licensing talks with overseas pharmaceutical firms and clinical progress in atopic dermatitis and Alzheimer's.

The bearish factors are continuing operating losses, unconfirmed licensing deals, the pending removal from the administrative list and the possibility of additional funding.

The company's targets of removal from the administrative list on December 3, 2026 and overseas sales of KRW 5 billion in the second half of 2026 are facts that can be checked. The 2026 annual report, due by the end of March 2027, will show on an annual basis how much the beauty business reduced the operating loss.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. getnews.co.kr
  3. alphasquare.co.kr
  4. news.nate.com
  5. getnews.co.kr
  6. biotimes.co.kr
  7. biotimes.co.kr
  8. getnews.co.kr
  9. newspim.com
  10. viva100.com
  11. tradingkey.com
  12. vegannews.co.kr
  13. kr.investing.com
  14. m.thinkpool.com
  15. prnewswire.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis